drugset / Trial / NCT03375021
CX717 in the Treatment of Adult ADHD
RandomizedCrossoverQuadruple-blindTreatment
Summary
A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder
Timeline
- Start
- 2005-07-19
- Primary completion
- 2006-01-10
- Completion
- 2006-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CX717 | Small molecule | 200 mg | — |
| Subject | CX717 | Small molecule | 800 mg | — |